Body composition and the obesity paradox in clear cell renal cell carcinoma
Body composition and the obesity paradox in clear cell renal cell carcinoma
批准号:
10675702
负责人:
Anna Helena Furberg-Barnes
金额:
$58.74万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-08-01 至 2025-07-31
关键词:
AccountingAddressAdipose tissueAffectAgeAmerican Society of Clinical OncologyArchivesAreaBehavior TherapyBehavioralBiologicalBiological ProcessBody CompositionBody SizeBody WeightBody mass indexBody measure procedureCancer PatientCancer SurvivorshipClassificationClear cell renal cell carcinomaClinicalColorectal CancerDataDevelopmentDiseaseFatty acid glycerol estersFutureGene ChipsGene ExpressionGenesGenetic TranscriptionGuidelinesImmuneImmune systemImmunologicsImmunotherapyIncidenceInflammatoryInterventionLinkLongterm Follow-upMalignant NeoplasmsMeasurementMediatingMemorial Sloan-Kettering Cancer CenterMessenger RNAMetabolicMetabolic DiseasesModelingMolecularMolecular EpidemiologyMuscleNephrectomyNonmetastaticNutritionalObesityObesity EpidemicOutcomePathway interactionsPatient SelectionPatientsPharmacological TreatmentPopulationPositioning AttributePrognosisPrognostic FactorRecommendationRenal carcinomaResearchResearch PersonnelRiskRisk FactorsScanningSkeletal MuscleSmokingSpecimenTimeTissuesTumor MarkersTumor SubtypeUp-RegulationVisceralWeightX-Ray Computed Tomographycancer epidemiologyclinically relevantcomorbiditydensitydesigndisease heterogeneityenergy balanceepidemiology studyhigh body mass indeximmune cell infiltrateimprovedindividual patientinsightmolecular scalemolecular subtypesmortalitymortality risknovelnovel strategiespatient populationpatient subsetspharmacologicpredict clinical outcomeprematureprognostic modelprogression riskresistance exerciseresponserisk predictionrisk prediction modelsexsubcutaneoustertiary preventiontherapy designtranscriptomicstreatment responsetreatment trialtumorurologic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Clear cell renal cell carcinoma (ccRCC) is the most lethal urologic malignancy and its incidence is increasing.
The proposed molecular epidemiology study moves beyond body mass index (BMI) to identify ccRCC patients
at risk of poor prognosis while considering molecular tumor subtype based on gene expression, and is in direct
response to an ASCO position statement that calls for more obesity-related research to ultimately inform
weight recommendations and refine prognostic factors for cancer patients. The inverse association between
BMI and mortality that is consistently observed among ccRCC patients presents a significant clinical challenge
for patients, clinicians, and researchers because it is not clear how to interpret it. Mechanisms underlying the
obesity paradox remain largely unexplored. In the proposed study, we will derive new body composition
variables from existing, pre-surgical computed tomography (CT) scans, and transcriptomically-characterize the
archived tumor specimens from 1200 non-metastatic ccRCC patients who were treated by nephrectomy at
Memorial Sloan Kettering Cancer Center between 1995-2017 and followed for clinical outcomes. Based on
strong preliminary data we hypothesize that the obesity paradox is influenced by disease heterogeneity and
specific body composition features including low skeletal muscle and visceral adipose tissue radiodensity. In
Aim 1 we will examine how body composition variables (i.e., area and density of skeletal muscle and adipose
tissues) are associated with BMI and with validated ccRCC molecular tumor subtypes that are strongly
associated with prognosis. In Aim 2 we will identify which aspects of body composition are independently
associated with survival after accounting for molecular tumor subtype. By exploring how tumor RNA expression
of immunologic, inflammatory, angiogenic and other cancer-related genes differ by body composition and
survival in Aim 3, we will not only further our understanding of the link between body size and biological
processes, but may also identify novel targets for tertiary prevention studies. The proposed research has the
potential to make a lasting impact on the fields of cancer epidemiology and survivorship by clarifying the
clinical interpretation of the obesity paradox, identifying novel prognostic factors derived from readily available
CT scans, and informing the development of future behavioral or pharmacological interventions designed to
improve clinical outcomes for the growing population of ccRCC patients.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.urolonc.2020.03.017
发表时间:
2020-09
期刊:
Urologic oncology
影响因子:
--
作者:
[Sanchez A, Kissel S, Coletta A, Scott J, Furberg H]
通讯作者:
Furberg H
DOI:
10.1016/j.acra.2021.06.005
发表时间:
2022-03
期刊:
ACADEMIC RADIOLOGY
影响因子:
4.8
作者:
[Kelly, Ciara R., Mourtzakis, Marina, Furberg, Helena, Tandon, Puneeta, Paris, Michael T.]
通讯作者:
Paris, Michael T.
Body composition and the obesity paradox in clear cell renal cell carcinoma
-
批准号:10228024
-
项目类别:
-
资助金额:$65.33万
-
财政年份:2019
-
负责人:Anna Helena Furberg-Barnes
-
依托单位:
Body composition and the obesity paradox in clear cell renal cell carcinoma
-
批准号:10453737
-
项目类别:
-
资助金额:$63.23万
-
财政年份:2019
-
负责人:Anna Helena Furberg-Barnes
-
依托单位:
Body composition and the obesity paradox in clear cell renal cell carcinoma
-
批准号:9980319
-
项目类别:
-
资助金额:$78.81万
-
财政年份:2019
-
负责人:Anna Helena Furberg-Barnes
-
依托单位:
The Genetic Epidemiology of Nicotine Dependence
-
批准号:7272725
-
项目类别:
-
资助金额:$12.94万
-
财政年份:2006
-
负责人:Anna Helena Furberg-Barnes
-
依托单位:
The Genetic Epidemiology of Nicotine Dependence
-
批准号:7937973
-
项目类别:
-
资助金额:$10.81万
-
财政年份:2006
-
负责人:Anna Helena Furberg-Barnes
-
依托单位:
The Genetic Epidemiology of Nicotine Dependence
-
批准号:7141387
-
项目类别:
-
资助金额:$12.65万
-
财政年份:2006
-
负责人:Anna Helena Furberg-Barnes
-
依托单位:
The Genetic Epidemiology of Nicotine Dependence
-
批准号:7658776
-
项目类别:
-
资助金额:$13.32万
-
财政年份:2006
-
负责人:Anna Helena Furberg-Barnes
-
依托单位:
The Genetic Epidemiology of Nicotine Dependence
-
批准号:7459875
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2006
-
负责人:Anna Helena Furberg-Barnes
-
依托单位:
海外基金